NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.

Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking ...

Hims & Hers bounced back by 8.64 percent on Monday to close at $52.03 following announcements that it remains open to working ...

The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...

Danish pharmaceutical company Novo Nordisk (NVO) on Tuesday said that it has submitted an application to the European ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

On April 29, Novo Nordisk (NVO-2.93%) and Hims & Hers Health (HIMS-4.66%) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Hims & Hers stock soared on ...

Novo Nordisk has launched its wildly popular weight-loss drug Wegovy in more than 15 countries since 2021 at prices ranging from $200 to almost $2,000 a month, as Eli Lilly also began selling its ...

Novo Nordisk, maker of the popular weight-loss drug Wegovy, says it has started to increase the availability of the drug for people in the United States. CNN values your feedback 1.

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...